Lesson plan
Temelimab
Temelimab (also known as GNbAC1 ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W. It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.
Article summary
Temelimab (also known as GNbAC1 ) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W. It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions. As of 2023, it is also being studied for cognitive impairment in long COVID.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.